MARKET COMPOSITE
Pharmaceuticals: Other Stocks20-30-2024 21:30:00 PM
Price
$106.35
-1.21%
The list of companies include ACB-Aurora Cannabis Inc, ACRS-Aclaris Therapeutics Inc, ACRX-Acelrx Pharmaceuticals Inc, ACST-Acasti Pharma Inc, ADMP-Adamis Pharmaceuticals Corp, AGRX-Agile Therapeutics Inc, ALBO-Albireo Pharma Inc, AMPE-Ampio Pharmaceuticals Inc, AMPH-Amphastar Pharmaceuticals Inc, ANIK-Anika Therapeutics Inc., ANIP-ANI Pharmaceuticals Inc, ASMB-Assembly Biosciences Inc, AXSM-Axsome Therapeutics Inc, BHC-Bausch Health Companies Inc, BRBR-Bellring Brands Inc, COLL-Collegium Pharmaceutical Inc, CORT-Corcept Therapeutics Inc, CPIX-Cumberland Pharmaceuticals Inc., CPRX-Catalyst Pharmaceuticals Inc, CRON-Cronos Group Inc, CTIC-CTI BioPharma Corp, CTLT-Catalent Inc., DRRX-Durect Corp, EGRX-Eagle Pharmaceuticals Inc, EVOK-Evoke Pharma Inc, GLMD-Galmed Pharmaceuticals Ltd, HAPP-Happiness Biotech Group Ltd, HEPA-Hepion Pharmaceuticals Inc, HEXO-HEXO Corp, HROW-Harrow Health Inc
* Latest intraday update before market close @ 20:45:41 PM 02/20/2024
Summary
:
Average return is down -1.3%
Median return is down -1.2%
17 out of 48 stocks are up (limited to those with intraday pricing feeds).
Top Movers
:
AGRX -14.2%AXSM -13.5%KALV -6.8%SAVA -5.5%INNV -5.4%SAGE -4.6%MRNS -4.4%OGI -4.4%ACST -3.6%BRBR -3.1%AMPH -3.0%ACRS -2.9%

Aggregated price index with volume information

Summary:

  • Pharmaceuticals: Other stocks down 1.2% on average while median return down 0.9% in a day
  • Pharmaceuticals: Other stocks down 0.9% on average while median return down 0.6% in a week
  • Pharmaceuticals: Other stocks up 6.1% on average while median return up 1.4% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks
Ticker
1d
7d
30d
PE Ratio
PE/G
P/B (mrq)
P/S (ttm)
Earning Growth
MarketCap
Short %
Held By Institutions %
RSI
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
MYSZ13.6%
14.8%
6.7%
2.55138.481.9M4%3%55\103-0.6%
SLN10.3%
7.3%
32.9%
140.98728.8M9%73-\/At resistance671.9%
HROW7.7%
-2.0%
21.3%
12.737.674.22403.9M9%57%62-/\/\Above resistance213-0.3%
QLGN6.9%
9.2%
1.0%
13.662.6M6%7%50\/-\Above resistance52-0.8%
EVOK4.4%
2.7%
-7.8%
-0.175.93408.072.4M3%14%46\54-0.8%
SCYX2.9%
-2.2%
-3.3%
1.185.9712.8466M13%53%41\-/\114-0.4%
PCRX2.7%
-0.5%
-6.2%
204.520.654.035.9327%1.4B20%118%46/-\213-0.1%
OPT2.4%
0.3%
9.4%
1534.81253.5M21%\/180.7%
ACRS1.7%
-1.6%
6.1%
-0.73-0.2621.90146.9786.4M3%64%51\/-\213-0.4%
IRWD1.7%
-3.5%
17.0%
-2.30.1517.244.761094%2.3B22%108%62\/\/Above resistance2130.0%
TBPH1.4%
4.0%
-5.8%
-9.36-0.2917.26444.2M10%83%43\/\213-0.0%
BHC1.1%
2.6%
5.5%
-3.261.21.313.1B6%72%65\/\/2130.1%
RGLS1.0%
-6.4%
26.6%
-0.132.426.5831.2M10%50%62/\Above resistance107-0.0%
PRGO0.9%
-0.2%
-2.3%
-1070.21.641.111.24-64%4.4B7%86%51\213-0.1%
ARGX0.8%
0.7%
7.8%
-0.4711.09302.0123.4B51%53/Below support2130.1%
MDWD0.4%
5.3%
0.9%
-8.71-0.1827.125.64166.6M0%20%62\-/590.9%
EGRX0.3%
7.0%
33.7%
6.65.32.953.0777.5M13%96%59\/-\213-0.4%
ORMP0.3%
-0.6%
41.6%
7.92154.89127.1M9%10%66-/-213-0.3%
ANIK0.2%
1.0%
9.0%
-14.45100.522.104.40355.5M14%99%57\/\/\Above resistance213-0.1%
CPIX0.0%
2.4%
8.8%
-13.861.350.961.1331.8M1%22%55
* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.
* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.
* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.

Related ETFs (click on ticker for stock detail page)

Detail Performance Summary
  • 1M winners are : Winners for past month are $OCUL 95.3%, $ORMP 41.6%, $EGRX 33.7%, $SLN 32.9%, $ACST 27.5%
  • 1M losers are : Losers for past month are $BLRX -11.0%, $SAGE -14.8%, $SAVA -14.9%, $INNV -15.7%, $AGRX -27.8%
  • 1W winners are : Winners for past week are $OCUL 27.9%, $ACST 19.2%, $SLN 7.3%, $EGRX 7.0%, $MDGL 6.2%
  • 1W losers are : Losers for past week are $SAVA -9.8%, $AGRX -11.8%, $KALV -14.0%, $AXSM -16.9%, $INNV -17.0%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 14.2%, for the past 3 months is 11.3%

In the past month for a 5 days rolling window, the highest corrrelation is 32.2%, the lowest correlation is -1.1%, the latest correlation is 26.7%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 73.9% between CPRX and INVA

The lowest correlation is -67.7% between HZNP and ICPT

Stock news

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:

    REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results

    United Therapeutics (UTHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Oramed Letter to Shareholders02-20-2024 13:30:00 PM

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

    RADNOR, Pa., February 20, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on March 5, 2024. The Company will host a conference call at 4:30 p.m. E.T. on March 5, 2024, to provide a business update and discuss financial results.

    CAMBRIDGE, Mass. & SALISBURY, England, February 20, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (

    Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Bio

    Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani i

    BellRing Brands (BRBR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Get a deeper insight into the potential performance of United Therapeutics (UTHR) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.